AR and breast carcinoma: This concept was initially studied in the phase II Translational Breast Cancer Research Consortium (TBCRC 011) trial that explored the role of bicalutamide among androgen receptor (AR)-positive, ER- and PR-negative metastatic breast cancer [53].